BRIEF-Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources On Its Lead Clinical Program, Pyx-201

Reuters2024-12-20

Dec 19 (Reuters) - Pyxis Oncology Inc PYXS.O:

PYXIS ONCOLOGY ANNOUNCES PORTFOLIO PRIORITIZATION, FOCUSING RESOURCES ON ITS LEAD CLINICAL PROGRAM, PYX-201
PYXIS ONCOLOGY INC - - COMPANY
PYXIS ONCOLOGY INC - CURRENT CASH RUNWAY EXPECTED TO FUND DEVELOPMENT INTO 2H 2026
PYXIS ONCOLOGY INC - WILL FOCUS RESOURCES ON ADVANCING ITS LEAD ASSET, PYX-201
PYXIS ONCOLOGY INC - SECOND CLINICAL PROGRAM, PYX-106 IS BEING DEPRIORITIZED

Source text: ID:nGNX9fJPzf

Further company coverage: PYXS.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492846014?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-20 05:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492846014","market":"us","top_or_hot":-1,"title":"BRIEF-Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources On Its Lead Clinical Program, Pyx-201","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources On Its Lead Clinical Program, Pyx-201</title></head><body><p><span>Dec 19 (Reuters)</span><span> - </span>Pyxis Oncology Inc <span>PYXS.O</span>:</p><ul><li><p>PYXIS ONCOLOGY ANNOUNCES PORTFOLIO PRIORITIZATION, FOCUSING RESOURCES ON ITS LEAD CLINICAL PROGRAM, PYX-201</p></li><li><p>PYXIS ONCOLOGY INC - - COMPANY</p></li><li><p>PYXIS ONCOLOGY INC - CURRENT CASH RUNWAY EXPECTED TO FUND DEVELOPMENT INTO 2H 2026</p></li><li><p>PYXIS ONCOLOGY INC - WILL FOCUS RESOURCES ON ADVANCING ITS LEAD ASSET, PYX-201</p></li><li><p>PYXIS ONCOLOGY INC -  SECOND CLINICAL PROGRAM, PYX-106 IS BEING DEPRIORITIZED</p></li></ul><p>Source text: <span>ID:nGNX9fJPzf</span></p><p>Further company coverage: <span>PYXS.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources On Its Lead Clinical Program, Pyx-201</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources On Its Lead Clinical Program, Pyx-201\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-20 05:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nFWN3NK1BK:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BRIEF-Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources On Its Lead Clinical Program, Pyx-201Dec 19 (Reuters) - Pyxis Oncology Inc PYXS.O:PYXIS ONCOLOGY ANNOUNCES PORTFOLIO ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nFWN3NK1BK:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PYXS","symbol_name":"Pyxis Oncology, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nFWN3NK1BK:1","article_id":"2492846014","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492846014","pubTimestamp":1734643666,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources On Its Lead Clinical Program, Pyx-201Dec 19 (Reuters) - Pyxis Oncology Inc PYXS.O:PYXIS ONCOLOGY ANNOUNCES PORTFOLIO PRIORIT","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PYXS":"Pyxis Oncology, Inc.","BK4139":"生物科技"},"translate_title":"简介-Pyxis Oncology宣布产品组合优先级，将资源集中在其主要临床项目Pyx-201上","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PYXS":0.9},"content_text":"BRIEF-Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources On Its Lead Clinical Program, Pyx-201Dec 19 (Reuters) - Pyxis Oncology Inc PYXS.O:PYXIS ONCOLOGY ANNOUNCES PORTFOLIO PRIORITIZATION, FOCUSING RESOURCES ON ITS LEAD CLINICAL PROGRAM, PYX-201PYXIS ONCOLOGY INC - - COMPANYPYXIS ONCOLOGY INC - CURRENT CASH RUNWAY EXPECTED TO FUND DEVELOPMENT INTO 2H 2026PYXIS ONCOLOGY INC - WILL FOCUS RESOURCES ON ADVANCING ITS LEAD ASSET, PYX-201PYXIS ONCOLOGY INC -  SECOND CLINICAL PROGRAM, PYX-106 IS BEING DEPRIORITIZEDSource text: ID:nGNX9fJPzfFurther company coverage: PYXS.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492846014"}